Microplastics and Misinformation: What Science Really Says
November 12, 2025
Brand Name :
Dayvigo
Synonyms :
lemborexant
Class :
Sedative/Hypnotics; Orexin Antagonists
Dosage Forms & StrengthsÂ
Schedule IV tablet:Â
10mgÂ
5mgÂ
5 mg orally not more than once each night, just before going back to bed, with a minimum of 7 hours before the scheduled time of awakening remaining
Based on the clinical response and tolerability, the dosage can be increased upto 10 mg.
Safety and efficacy not establishedÂ
5 mg orally not more than once each night, just before going back to bed, with a minimum of 7 hours before the scheduled time of awakening remaining
Based on the clinical response and tolerability, the dosage can be increased up to 10 mg
Dosage Forms & StrengthsÂ
Schedule IV tablet:Â
10mgÂ
5mgÂ
lemborexant may enhance the CNS depressant effect of CNS depressants
lemborexant may enhance the CNS depressant effect of CNS depressants
lemborexant may enhance the CNS depressant effect of CNS depressants
lemborexant may enhance the CNS depressant effect of CNS depressants
lemborexant may enhance the CNS depressant effect of CNS depressants
may enhance the serum concentration of CYP3A4 inhibitors
may enhance the serum concentration of CYP3A4 inhibitors
may enhance the serum concentration of CYP3A4 inhibitors
may enhance the serum concentration of CYP3A4 inhibitors
may enhance the serum concentration of CYP3A4 inhibitors
may have an increased CNS depressive effect when combined with CNS depressants
may have an increased CNS depressive effect when combined with CNS depressants
may have an increased CNS depressive effect when combined with CNS depressants
may have an increased CNS depressive effect when combined with CNS depressants
may have an increased CNS depressive effect when combined with CNS depressants
lemborexant: they may increase the CNS depressant effect of CNS Depressants
lemborexant: they may increase the CNS depressant effect of CNS Depressants
lemborexant: they may increase the CNS depressant effect of CNS Depressants
may enhance the concentration of serum when combined with lemborexant
may increase the QTc-prolonging effect of each other when combined
may increase the QTc-prolonging effect of each other when combined
may increase the QTc-prolonging effect of each other when combined
may increase the QTc-prolonging effect of each other when combined
may increase the QTc-prolonging effect of each other when combined
lemborexant: they may increase the CNS stimulant effect of CNS stimulants
lemborexant: they may increase the CNS stimulant effect of CNS stimulants
lemborexant: they may increase the CNS stimulant effect of CNS stimulants
may decrease the therapeutic effect when combined with anti-parkinson agents
may decrease the therapeutic effect when combined with anti-parkinson agents
may decrease the therapeutic effect when combined with anti-parkinson agents
may decrease the therapeutic effect when combined with anti-parkinson agents
lemborexant: they may enhance the serum concentration of CYP2D6 Inhibitors
lemborexant: they may enhance the serum concentration of CYP2D6 Inhibitors
lemborexant: they may enhance the serum concentration of CYP2D6 Inhibitors
lemborexant: they may enhance the serum concentration of CYP2D6 Inhibitors
lemborexant: they may enhance the serum concentration of CYP2D6 Inhibitors
may enhance the risk of CNS depression when combined
may enhance the risk of CNS depression when combined
may enhance the risk of CNS depression when combined
may enhance the risk of CNS depression when combined
may enhance the risk of CNS depression when combined
may enhance the serum concentration of CYP3A4 inhibitors
may increase the CNS depressant effect
may increase the CNS depressant effect of CNS depressants
may increase the toxic effects of agents with seizure threshold, lowering potential
may increase the CNS depressant effect of CNS depressants
acrivastine and pseudoephedrineÂ
may increase the hypertensive effects of sympathomimetics
may increase the CNS depressant effect of CNS depressants
may enhance the serum concentration of CYP3A4 inhibitors
may enhance the serum concentration of CYP3A4 inhibitors
may increase the CNS depressant effect of CNS depressants
may increase the CNS depressant effect of CNS depressants
may increase the CNS depressant effect of CNS depressants
may increase the CNS depressant effect of CNS depressants
may increase the CNS depressant effect of CNS depressants
promethazine/dextromethorphanÂ
may increase the CNS depressant effect of CNS Depressants
may increase the CNS depressant effect of CNS Depressants
may increase the CNS depressant effect of CNS Depressants
may increase the CNS depressant effect of CNS Depressants
may increase the CNS depressant effect of CNS Depressants
may enhance the serum concentration of CYP3A4 Inhibitors
may increase the CNS depressant effect of CNS Depressants
acetaminophen/doxylamine/dextromethorphanÂ
may increase the CNS depressant effect CNS Depressants
ciprofloxacin inhaled (Pending FDA approval)Â
may increase the serum concentration of CYP3A4 inhibitors
may diminish the concentration of serum when combined with lemborexant
may diminish the concentration of serum when combined with lemborexant
may diminish the concentration of serum when combined with lemborexant
may diminish the concentration of serum when combined with lemborexant
may diminish the concentration of serum when combined with lemborexant
It may enhance the sedation when combined with tasimelteon
lemborexant: they may enhance the serum concentration of CYP3A Inhibitors
lemborexant: they may enhance the serum concentration of CYP3A Inhibitors
lemborexant: they may enhance the serum concentration of CYP3A Inhibitors
lemborexant: they may enhance the serum concentration of CYP3A Inhibitors
lemborexant: they may enhance the serum concentration of CYP3A Inhibitors
the effect of lemborexant is increased by lenvatinib by altering intestinal or hepatic CYP3A4 enzyme metabolism
lemborexant increases the effect of lapatinib by altering the intestinal or hepatic CYP3A4 enzyme metabolism
CYP3A strong enhancers of the small intestine may reduce the bioavailability of lemborexant
it increases the toxicity of antipsychotic agents
may have an increasingly adverse effect when combined with antipsychotic agents
amisulpiride: they may increase the toxic effect of antipsychotic agents
antihypertensive drugs may enhance the hypotensive effect of antipsychotic Agents
antihypertensive drugs may enhance the hypotensive effect of antipsychotic Agents
antihypertensive drugs may enhance the hypotensive effect of antipsychotic Agents
antihypertensive drugs may enhance the hypotensive effect of antipsychotic Agents
antihypertensive drugs may enhance the hypotensive effect of antipsychotic Agents
may increase the effect of beta-blockers
may reduce the therapeutic effect of antiparkinson drugs
may reduce the therapeutic effect of antiparkinson drugs
may reduce the therapeutic effect of antiparkinson drugs
may reduce the therapeutic effect of antiparkinson drugs
may reduce the therapeutic effect of antiparkinson drugs
may have an increased hypotensive effect when combined with beta-blockers
may have an increased hypotensive effect when combined with beta-blockers
may have an increased hypotensive effect when combined with beta-blockers
may have an increased hypotensive effect when combined with beta-blockers
may have an increased hypotensive effect when combined with beta-blockers
may increase the risk of adverse effect of amphetamines
may increase the risk of adverse effect of amphetamines
may increase the risk of adverse effect of amphetamines
may increase the risk of adverse effect of amphetamines
may increase the risk of adverse effect of amphetamines
may diminish the therapeutic effect of the drug
may diminish the therapeutic effect of the drug
may diminish the therapeutic effect of the drug
may diminish the therapeutic effect of the drug
may diminish the therapeutic effect of the drug
may diminish the therapeutic effect of the drug
may diminish the therapeutic effect of the drug
may have an increased adverse effect when combined with antipsychotic agents
may have an increased adverse effect when combined with antipsychotic agents
may have an increased adverse effect when combined with antipsychotic agents
may have an increased adverse effect when combined with antipsychotic agents
may have an increased adverse effect when combined with antipsychotic agents
may increase the hypotensive effect of antipsychotic agents
may increase the hypotensive effect of antipsychotic agents
may increase the hypotensive effect of antipsychotic agents
may increase the hypotensive effect of antipsychotic agents
may increase the hypotensive effect of antipsychotic agents
seizure lowering agents increase the toxic or adverse effects of other antipsychotic agents
It may increase the neurotoxic effect of Antipsychotic Agents
antipsychotic agents may enhance the adverse/toxic effect of amphetamines
antipsychotic agents may enhance the adverse/toxic effect of amphetamines
antipsychotic agents may enhance the adverse/toxic effect of amphetamines
antacids may reduce the absorption of antipsychotic agents
antacids may reduce the absorption of antipsychotic agents
antacids may reduce the absorption of antipsychotic agents
antacids may reduce the absorption of antipsychotic agents
antacids may reduce the absorption of antipsychotic agents
may increase the hypotensive effect of beta-blockersÂ
may increase the hypotensive effect of beta-blockersÂ
may increase the hypotensive effect of beta-blockersÂ
may increase the hypotensive effect of beta-blockersÂ
may increase the hypotensive effect of beta-blockersÂ
may enhance the effect of antipsychotic agents
may enhance the effect of antipsychotic agents
may enhance the effect of antipsychotic agents
may enhance the effect of antipsychotic agents
may enhance the effect of antipsychotic agents
eprosartan/hydrochlorothiazideÂ
may increase the hypotensive effect of blood pressure-lowering agents
valsartan/hydrochlorothiazideÂ
may increase the hypotensive effect of blood pressure-lowering agents
may decrease the therapeutic effect when combined with antipsychotic agents
may have an increased adverse effect when combined with antipsychotic agents
it increases the toxicity of antipsychotic agents
may increase the arrhythmogenic effect of Inhalational Anaesthetics
may decrease the serum concentration of CYP3A4 Inducers
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may enhance the hypotensive effect
may enhance the hypotensive effect
may have an increasingly adverse effect when combined with amphetamines
may enhance the hypotensive effect of Blood Pressure Lowering Agents
may diminish the absorption when combined
metyrosine: they may increase the toxic effect of antipsychotic agents
may decrease the therapeutic effect of each other when combined
Acetylcholinesterase Inhibitors: they may increase the neurotoxic effect of antipsychotics
Acetylcholinesterase Inhibitors: they may increase the neurotoxic effect of antipsychotics
Could potentially amplify the neurotoxicity of antipsychotic agents
may have an increased hypotensive effect when combined with antipsychotic agents
may have an increased hypotensive effect when combined with antipsychotic agents
may have an increased hypotensive effect when combined with antipsychotic agents
itopride: they may increase the neurotoxic effect of antipsychotic agents
silodosin: they may decrease the therapeutic effect of antipsychotics
pholcodine: they may decrease the therapeutic effect of antipsychotics
may have an increasingly adverse effect when combined with Antipsychotic Agents
may have an increased neurotoxic effect when combined with antipsychotic agents
the effects on QT prolongation may be increased
may have an increased adverse effect when combined with antipsychotic agents
may have an increased adverse effect when combined with antipsychotic agents
may have an increased adverse effect when combined with antipsychotic agents
may have an increased adverse effect when combined with antipsychotic agents
may have an increased adverse effect when combined with antipsychotic agents
it increases the effect of CNS depressants
it increases the effect of CNS depressants
it increases the effect of CNS depressants
it increases the effect of CNS depressants
it increases the effect of CNS depressants
it increases the effect of CNS depressants
it increases the effect of CNS depressants
it increases the effect of CNS depressants
it increases the effect of CNS depressants
it increases the effect of CNS depressants
it increases the effect of CNS depressants
it increases the effect of CNS depressants
it increases the effect of CNS depressants
it increases the effect of CNS depressants
it increases the effect of CNS depressants
The potential for arrhythmogenic effects of mequitazine could be intensified by the presence of antipsychotic agents
Actions and spectrum:Â
lemborexant is a medication used for the treatment of insomnia. It belongs to orexin receptor antagonists. lemborexant works by blocking the action of orexin, a neuropeptide that plays a role in regulating wakefulness and sleep. By inhibiting the orexin signalling, lemborexant helps promote sleep and improve the overall quality and duration of sleep.Â
The spectrum of lemborexant’s action is primarily focused on insomnia, including difficulty falling asleep and staying asleep. It is used to treat insomnia and sleep maintenance. lemborexant can be used in adults for both short-term and long-term treatment of insomnia.Â
Frequency definedÂ
1-10%Â
10 mg /nightÂ
5 mg /nightÂ
<1%Â
10 mg /nightÂ
5 mg /nightÂ
Black Box Warning:Â
There were no black box warnings specifically associated with lemborexant.Â
Contraindication/Caution:Â
Contraindication:Â
Caution:Â
Comorbidities:Â
Pregnancy consideration: N/AÂ
Lactation: unknown Â
Pregnancy category:Â
Pharmacology:Â
lemborexant is a dual orexin receptor antagonist (DORA) that acts by selectively blocking the binding of orexins (hypocretins) to their receptors. Orexins are neuropeptides that play a role in promoting wakefulness and regulating the sleep-wake cycle.Â
The pharmacological effects of lemborexant are mediated through its antagonism of the orexin receptors, specifically orexin receptor 1 (OX1R) and orexin receptor 2 (OX2R). By blocking the action of orexins, lemborexant inhibits wake-promoting signals and promotes sleep.Â
lemborexant exhibits high selectivity for OX1R and OX2R, with greater affinity for OX2R. By selectively targeting these receptors, lemborexant helps regulate the sleep-wake cycle without affecting other neurotransmitter systems involved in sedation or hypnotic effects.Â
The exact mechanism by which lemborexant promotes sleep is fully not known, but it is believed to involve the inhibition of wakefulness-promoting centers in the brain, the reduction of orexin-mediated arousal signals, and the promotion of sleep-inducing processes. Â
Pharmacodynamics:Â
Orexins, also known as hypocretins, are neuropeptides that play a major role in regulating the sleep-wake cycle and promoting wakefulness. They are primarily produced in the lateral hypothalamus and act on orexin receptors in various brain regions, including the arousal-promoting centers.Â
By blocking the orexin receptors, lemborexant inhibits the wake-promoting effects of orexins, resulting in a decrease in wakefulness and an increase in sleep propensity. This mechanism helps to regulate the sleep-wake cycle and promote consolidated and restful sleep.Â
Additionally, lemborexant has a high selectivity for the OX2R subtype, which is believed to be the primary mediator of the hypnotic effects. The inhibition of OX2R by lemborexant further contributes to its sleep-promoting properties.Â
The precise pharmacodynamic effects of lemborexant on other neurotransmitter systems or brain regions are not fully understood. Â
Pharmacokinetics:Â
AbsorptionÂ
lemborexant is orally administered and is well-absorbed from the gastrointestinal tract. The maximum plasma concentration (Cmax) is reached within 1-3 hours after administration. The bioavailability of lemborexant is approximately 76%.Â
DistributionÂ
lemborexant has a moderate volume of distribution, indicating that it distributes well into body tissues. It is extensively bound to plasma proteins, to albumin.Â
MetabolismÂ
lemborexant is primarily metabolized in the liver by cytochrome P450 enzymes, specifically CYP3A4 and CYP3A5. The major metabolic pathway involves oxidation and subsequent glucuronidation. The metabolites formed are pharmacologically inactive.Â
Elimination and excretionÂ
The elimination of lemborexant occurs primarily through the feces (approximately 88%) and to a lesser extent through urine (approximately 5%). The elimination half-life of lemborexant is approximately 17 hours.Â
Administration:Â
lemborexant is available as an oral tablet and should be taken by mouth.Â
Patient information leafletÂ
Generic Name: lemborexantÂ
Pronounced: (lem-boh-REX-ant)Â Â
Why do we use lemborexant?Â
lemborexant is a medication primarily used to treat insomnia. It belongs to orexin receptor antagonists, which work by blocking the action of orexin, a neurotransmitter involved in promoting wakefulness.Â
The main use of lemborexant is to help improve sleep onset and sleep maintenance in adults with insomnia. Lemborexant is typically prescribed for short-term use, usually 1 to 4 weeks.Â